WallStreetZenWallStreetZen

NASDAQ: SMMT
Summit Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for SMMT

Based on 1 analyst offering 12 month price targets for Summit Therapeutics Inc.
Min Forecast
$8.00+122.84%
Avg Forecast
$8.00+122.84%
Max Forecast
$8.00+122.84%

Should I buy or sell SMMT stock?

Based on 1 analyst offering ratings for Summit Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SMMT stock forecasts and price targets.

SMMT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-26

1 of 1

Forecast return on equity

Is SMMT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is SMMT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

SMMT revenue forecast

What is SMMT's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$9.7M
Avg 2 year Forecast
$108.0M
Avg 3 year Forecast
$386.7M

SMMT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SMMT$3.59$8.00+122.84%Strong Buy
JANX$48.21$58.14+20.60%Strong Buy
MRUS$41.97$61.33+46.14%Strong Buy
CGON$36.05$61.75+71.29%Strong Buy
RYTM$39.71$52.25+31.58%Strong Buy
View Top Biotech Stocks

Summit Therapeutics Stock Forecast FAQ

Is Summit Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: SMMT) stock is to Strong Buy SMMT stock.

Out of 1 analyst, 1 (100%) are recommending SMMT as a Strong Buy, 0 (0%) are recommending SMMT as a Buy, 0 (0%) are recommending SMMT as a Hold, 0 (0%) are recommending SMMT as a Sell, and 0 (0%) are recommending SMMT as a Strong Sell.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.

What is SMMT's revenue growth forecast for 2026-2028?

(NASDAQ: SMMT) Summit Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Summit Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast SMMT's revenue for 2026 to be $6,806,462,636, with the lowest SMMT revenue forecast at $6,806,462,636, and the highest SMMT revenue forecast at $6,806,462,636. On average, 1 Wall Street analysts forecast SMMT's revenue for 2027 to be $75,783,295,332, with the lowest SMMT revenue forecast at $75,783,295,332, and the highest SMMT revenue forecast at $75,783,295,332.

In 2028, SMMT is forecast to generate $271,346,299,119 in revenue, with the lowest revenue forecast at $271,346,299,119 and the highest revenue forecast at $271,346,299,119.

What is SMMT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: SMMT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is SMMT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SMMT price target, the average SMMT price target is $8.00, with the highest SMMT stock price forecast at $8.00 and the lowest SMMT stock price forecast at $8.00.

The Wall Street analyst predicted that Summit Therapeutics's share price could reach $8.00 by Mar 26, 2025. The average Summit Therapeutics stock price prediction forecasts a potential upside of 122.84% from the current SMMT share price of $3.59.

What is SMMT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: SMMT) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.